[Proteic profiling SELDI-TOF and breast cancer: clinical potential applications].
Significant advances in early diagnosis, prognostic markers, therapeutic response and toxic effect indicators, together with the identification of new potential drug targets, have improved the survival of patients with breast cancer. Proteomic technologies, including SELDI-TOF (surface enhanced laser desorption/ionization-time of flight) mass spectrometry, are emerging tools that may contribute to better reach these key objectives.
Centre de Recherche en Cancérologie de Marseille, Département de Pharmacologie Moléculaire, Institut Paoli-Calmettes (IPC) et Inserm UMR 599, Marseille, France. goncalvesa@marseille.fnclcc.fr
Anthony
A
Gonçalves
François
F
Bertucci
Daniel
D
Birnbaum
Jean-Paul
JP
Borg
D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000175:diagnosis; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D009363:Neoplasm Proteins / Q000097:blood*; D011379:Prognosis; D040901:Proteomics / Q000379:methods*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000295:instrumentation / Q000379:methods*
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins